Navigation Links
Cardio Vascular Medical Device Announces Forward Stock Split
Date:12/2/2009

HAIFA, Isreal, December 2 /PRNewswire-FirstCall/ -- Cardio Vascular Medical Device Corp. (CVSL.OB), a leading developer of advanced cardiovascular surgery technology, today announced that the company's Board of Directors approved a one-for-three forward stock split, in the form of a stock dividend, payable to Cardio Vascular Medical Device shareholders.

The Company will announce in due course the estimated date the stock split will be payable and the related record date of the shareholders. The stock split is subject to FINRA approval. When the forward stock split becomes effective, shareholders of common stock will receive an additional two shares for each share held at the record date.

"We are pleased to announce this forward stock split for our shareholders," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "We expect that the Board's decision will improve liquidity and trading volume in our company's stock."

About Cardio Vascular Medical Device

Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.

Learn more about Cardio Vascular Medical Device at: http://www.cvslmedical.com

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated in the forward-looking statements. Cardio Vascular Medical Device Corp. public filings may be viewed at http://www.sec.gov.


    Contact:

    Alex Traiman
    Media Relations
    +1-646-863-9729

    Asher Zwebner
    +972-54-464-6363
    asher@fxmng.com


SOURCE Cardio Vascular Medical Device Corp.


'/>"/>
SOURCE Cardio Vascular Medical Device Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Zargis Cardioscan(TM) Featured on The Early Show on CBS
2. CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads
3. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
4. Reportlinker Adds Cardiovascular Catheters and Systems - Global Market Opportunities
5. Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference
6. CardioGenics Holdings Inc. Featured in Medical Device Daily
7. eCardio Named One of Houstons Fastest Growing Technology Companies at the 2009 Houston Business Journal FastTech 50 Awards Luncheon
8. Cardio Vascular Medical Device Launches Corporate Website
9. Cardiogenesis Reports Third Quarter 2009 Results
10. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
11. ATS Medical to Participate in the 2009 Canaccord Adams Cardiovascular Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):